Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Fresenius Medical Care Deutschland GmbH | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Acute kidney injury (AKI) requiring renal replacement therapy is common in critically ill patients. The major causes of AKI are severe sepsis and septic shock requiring effective antibiotic treatment. Patients with sepsis on ICUs usually are haemodynamically instable so that renal replacement therapy is applied using continuous techniques. In recent years, the efficacy of renal replacement therapies has improved, namely by using regional citrate anticoagulation which improves filter lifetime and filter patency. At present, the extent of removal of antibiotic drugs using citrate-anticoagulated CVVHD in critically ill patients has not been investigated thoroughly. Thus, the investigators want to investigate
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Piperacillin/Tazobactam | Patients undergoing continuous veno-venous renal replacement therapy and treated with this antibiotics | ||
| Imipenem/Cilastatin | Patients undergoing continuous veno-venous renal replacement therapy and treated with this antibiotics |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Removal of antibiotic drugs during day 1 - 2 - 3 of citrate anticoagulated CVVHD (mg/d) | Total hemofilter clearance (ml/min) of imipenem/cilastatin and piperacillin/tazobactam on each treatment day during an 8-hour dosing interval using blood sided clearance - Total amount of antibiotic drug which is eliminated via the filter during 24 h using filter clearance and delivered dialysis dose during 24 h | up to three days |
| Filter patency during day 1 - 2 - 3 of citrate anticoagulated CVVHD | Filter patency is calculated as a function of the sieving coefficient for small solutes (i.e. creatinine and the respective antibiotic drugs) over the first 72 h, Sieving coefficient is without dimension | up to three days |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Intensive care patients with acute kidney injury requiring continous renal replacement therapy with citrate-anticoagulation
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Detlef Kindgen-Milles, Prof. | Department of Anesthesiology | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Prof. Kindgen-Milles | Düsseldorf | 40225 | Germany |
Not provided
| ID | Term |
|---|---|
| D058186 | Acute Kidney Injury |
| D001424 | Bacterial Infections |
| ID | Term |
|---|---|
| D051437 | Renal Insufficiency |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| D005261 |
| Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D001423 | Bacterial Infections and Mycoses |
| D007239 | Infections |